BR9510490A - Combined two-component system designed for use in a mustard ribonucleotide host pharmaceutical composition half component mutant enzyme process to control neoplastic cell growth in a plasmid host vector and cell polynucleotide sequence - Google Patents
Combined two-component system designed for use in a mustard ribonucleotide host pharmaceutical composition half component mutant enzyme process to control neoplastic cell growth in a plasmid host vector and cell polynucleotide sequenceInfo
- Publication number
- BR9510490A BR9510490A BR9510490A BR9510490A BR9510490A BR 9510490 A BR9510490 A BR 9510490A BR 9510490 A BR9510490 A BR 9510490A BR 9510490 A BR9510490 A BR 9510490A BR 9510490 A BR9510490 A BR 9510490A
- Authority
- BR
- Brazil
- Prior art keywords
- host
- component
- enzyme
- prodrug
- natural
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9426192.2A GB9426192D0 (en) | 1994-12-23 | 1994-12-23 | Chemical compounds |
GBGB9516810.0A GB9516810D0 (en) | 1995-08-16 | 1995-08-16 | Chemical compounds |
PCT/GB1995/002991 WO1996020011A1 (en) | 1994-12-23 | 1995-12-21 | Chemical compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
BR9510490A true BR9510490A (en) | 1998-01-13 |
BR9510490B1 BR9510490B1 (en) | 2010-10-05 |
Family
ID=26306259
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI9510490-9A BR9510490B1 (en) | 1994-12-23 | 1995-12-21 | structured two-component combined pharmaceutical composition for use in a host. |
Country Status (23)
Country | Link |
---|---|
US (1) | US5985281A (en) |
EP (1) | EP0806964B1 (en) |
JP (1) | JP3805365B2 (en) |
KR (1) | KR100270650B1 (en) |
CN (1) | CN1095677C (en) |
AT (1) | ATE222124T1 (en) |
AU (1) | AU701916B2 (en) |
BR (1) | BR9510490B1 (en) |
CA (1) | CA2205091A1 (en) |
CZ (1) | CZ195297A3 (en) |
DE (1) | DE69527805T2 (en) |
ES (1) | ES2181805T3 (en) |
FI (1) | FI972683A0 (en) |
HU (1) | HUT77450A (en) |
IL (1) | IL116511A0 (en) |
MX (1) | MX9704575A (en) |
NO (1) | NO972882L (en) |
NZ (1) | NZ297529A (en) |
PL (1) | PL184031B1 (en) |
RU (1) | RU2189251C2 (en) |
SK (1) | SK80997A3 (en) |
TR (1) | TR199501654A2 (en) |
WO (1) | WO1996020011A1 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0844885A2 (en) * | 1995-08-16 | 1998-06-03 | Zeneca Limited | Chemical compounds |
SG71046A1 (en) | 1996-10-10 | 2000-03-21 | Connector Systems Tech Nv | High density connector and method of manufacture |
AU6000698A (en) * | 1997-02-14 | 1998-09-08 | Zeneca Limited | Proteins |
GB9703201D0 (en) * | 1997-02-15 | 1997-04-02 | Zeneca Ltd | Chemical compounds |
GB9709421D0 (en) * | 1997-05-10 | 1997-07-02 | Zeneca Ltd | Chemical compounds |
US20040117863A1 (en) * | 1998-09-18 | 2004-06-17 | Edge Michael D. | Transgenically produced fusion proteins |
US6361774B1 (en) | 1999-09-17 | 2002-03-26 | Immunomedics, Inc. | Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug |
AU763628B2 (en) * | 1998-09-18 | 2003-07-31 | Immunomedics Inc. | Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug |
RU2002110121A (en) * | 1999-09-17 | 2004-03-10 | Джитиси Байотерапьютикс, Инк. (Us) | Fused Proteins Obtained by Transgenic Method |
EP1565564A4 (en) * | 2002-11-27 | 2006-06-07 | Gtc Biotherapeutics Inc | Modified antibodies stably produced in milk and methods of producing same |
US20080019905A9 (en) * | 2005-02-18 | 2008-01-24 | Strome Scott E | Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection |
ES2417147T3 (en) * | 2005-10-21 | 2013-08-06 | Revo Biologics, Inc. | Antibodies with enhanced antibody dependent cell cytotoxicity activity, methods for their production and use |
US20080031866A1 (en) * | 2006-06-20 | 2008-02-07 | Eichenbaum Gary M | Method for modulating the pharmacokinetics and metabolism of a therapeutic agent |
WO2007149827A2 (en) * | 2006-06-20 | 2007-12-27 | Janssen Pharmaceutica, N.V. | Method for modulating the pharmacokinetics and metabolism of a therapeutic agent |
EP2792670A1 (en) | 2006-10-03 | 2014-10-22 | Techfields Biochem Co. Ltd | Positively charged water-soluble prodrugs of mustards and related compounds with very high skin penetration rates |
GB0709333D0 (en) * | 2007-05-15 | 2007-06-20 | Smart Targeting Ltd | Binding protein |
EP2279003A4 (en) * | 2008-05-01 | 2013-04-03 | Gtc Biotherapeutics Inc | An anti-cd137 antibody as an agent in the treatment of inflammatory conditions |
US10745492B1 (en) | 2019-04-03 | 2020-08-18 | Ark Diagnostics, Inc. | Antibodies to symmetrically dimethylated arginine analytes and use thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8705477D0 (en) * | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
US4975278A (en) * | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5632990A (en) * | 1988-04-22 | 1997-05-27 | Cancer Research Campaign Tech. Ltd. | Treatment for tumors comprising conjugated antibody A5B7 and a prodrug |
GB8809616D0 (en) * | 1988-04-22 | 1988-05-25 | Cancer Res Campaign Tech | Further improvements relating to drug delivery systems |
US5433955A (en) * | 1989-01-23 | 1995-07-18 | Akzo N.V. | Site specific in vivo activation of therapeutic drugs |
EP0454783B1 (en) * | 1989-01-23 | 1995-06-07 | Akzo Nobel N.V. | Site specific in-vivo activation of therapeutic drugs |
AU674137B2 (en) * | 1992-01-30 | 1996-12-12 | Genzyme Limited | Chiral synthesis with modified enzymes |
GB9323429D0 (en) * | 1993-11-12 | 1994-01-05 | Wellcome Found | Therapy |
US5389537A (en) * | 1994-01-21 | 1995-02-14 | Wisconsin Alumni Research Foundation | Nuclease having altered specificity |
-
1995
- 1995-12-21 PL PL95320964A patent/PL184031B1/en not_active IP Right Cessation
- 1995-12-21 KR KR1019970704250A patent/KR100270650B1/en not_active IP Right Cessation
- 1995-12-21 CA CA002205091A patent/CA2205091A1/en not_active Abandoned
- 1995-12-21 WO PCT/GB1995/002991 patent/WO1996020011A1/en not_active Application Discontinuation
- 1995-12-21 RU RU97112396/14A patent/RU2189251C2/en not_active IP Right Cessation
- 1995-12-21 AU AU42697/96A patent/AU701916B2/en not_active Ceased
- 1995-12-21 ES ES95941214T patent/ES2181805T3/en not_active Expired - Lifetime
- 1995-12-21 JP JP52028496A patent/JP3805365B2/en not_active Expired - Fee Related
- 1995-12-21 AT AT95941214T patent/ATE222124T1/en not_active IP Right Cessation
- 1995-12-21 NZ NZ297529A patent/NZ297529A/en not_active IP Right Cessation
- 1995-12-21 MX MX9704575A patent/MX9704575A/en not_active IP Right Cessation
- 1995-12-21 CN CN95196986A patent/CN1095677C/en not_active Expired - Fee Related
- 1995-12-21 BR BRPI9510490-9A patent/BR9510490B1/en not_active IP Right Cessation
- 1995-12-21 DE DE69527805T patent/DE69527805T2/en not_active Expired - Lifetime
- 1995-12-21 CZ CZ971952A patent/CZ195297A3/en unknown
- 1995-12-21 US US08/860,882 patent/US5985281A/en not_active Expired - Lifetime
- 1995-12-21 EP EP95941214A patent/EP0806964B1/en not_active Expired - Lifetime
- 1995-12-21 SK SK809-97A patent/SK80997A3/en unknown
- 1995-12-21 HU HU9702280A patent/HUT77450A/en unknown
- 1995-12-22 IL IL11651195A patent/IL116511A0/en not_active IP Right Cessation
- 1995-12-22 TR TR95/01654A patent/TR199501654A2/en unknown
-
1997
- 1997-06-19 FI FI972683A patent/FI972683A0/en unknown
- 1997-06-20 NO NO972882A patent/NO972882L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
TR199501654A2 (en) | 1996-07-21 |
PL320964A1 (en) | 1997-11-24 |
CN1171054A (en) | 1998-01-21 |
NO972882D0 (en) | 1997-06-20 |
KR100270650B1 (en) | 2000-11-01 |
DE69527805D1 (en) | 2002-09-19 |
AU4269796A (en) | 1996-07-19 |
WO1996020011A1 (en) | 1996-07-04 |
EP0806964A1 (en) | 1997-11-19 |
ATE222124T1 (en) | 2002-08-15 |
DE69527805T2 (en) | 2003-04-24 |
BR9510490B1 (en) | 2010-10-05 |
NO972882L (en) | 1997-08-19 |
NZ297529A (en) | 1999-07-29 |
CZ195297A3 (en) | 1997-12-17 |
FI972683A (en) | 1997-06-19 |
US5985281A (en) | 1999-11-16 |
RU2189251C2 (en) | 2002-09-20 |
PL184031B1 (en) | 2002-08-30 |
AU701916B2 (en) | 1999-02-11 |
ES2181805T3 (en) | 2003-03-01 |
JP3805365B2 (en) | 2006-08-02 |
FI972683A0 (en) | 1997-06-19 |
CA2205091A1 (en) | 1996-07-04 |
EP0806964B1 (en) | 2002-08-14 |
JPH10511547A (en) | 1998-11-10 |
HUT77450A (en) | 1998-04-28 |
SK80997A3 (en) | 1998-02-04 |
MX9704575A (en) | 1997-10-31 |
CN1095677C (en) | 2002-12-11 |
TR199501654A3 (en) | 1996-07-21 |
IL116511A0 (en) | 1996-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9510490A (en) | Combined two-component system designed for use in a mustard ribonucleotide host pharmaceutical composition half component mutant enzyme process to control neoplastic cell growth in a plasmid host vector and cell polynucleotide sequence | |
BR0210225A (en) | Mutant immunogenic cholera holotoxin, immunogenic composition, method for enhancing a vertebrate host's immune response to an antigen, isolated and purified DNA sequence, nucleic acid molecule, host cell, method for producing a mutant immunogenic cholera holotoxin, and, use of a mutant cholera holotoxin | |
BR0210216A (en) | Immunogenic cholera holotoxin, mutant (ct-crm), immunogenic composition, methods to increase the immune response of a vertebrate host to an antigen, and to produce an immunogenic, mutant cholera holotoxin, isolated and purified nucleic acid molecule, sequence host cell, and use of a mutant cholera holotoxin | |
DK1724354T3 (en) | Circular DNA molecule with a dependent origin of replication, its method of preparation and its use in gene therapy | |
ATE323169T1 (en) | PLASMID FOR ADMINISTRATION OF NUCLEIC ACIDS AND METHOD OF USE | |
BR0113491A (en) | Isolated polynucleotide and polypeptide, expression vector, host cell, fusion protein, methods for stimulating and / or expanding tumor protein-specific T cells to stimulate an immune response in a patient, to treat cancer in a patient and to inhibit cancer development in a patient, isolated t-cell population, composition, and use of a component. | |
BR9812079A (en) | Salmonella sp. mutant, lipopolysaccharide, process to inhibit the growth or reduce the volume of a solid tumor cancer, pharmaceutical composition, and, improved process to select genetic alterations in a bacterium. | |
BR9406232A (en) | New agent to control cell activity | |
DE69406423D1 (en) | METHOD FOR DELIVERING AGENTS TO TARGET CELLS | |
BR0114576A (en) | Compound, pharmaceutical composition, use of a compound, method of treating a disease state and process for preparing a compound | |
BR9808769A (en) | Gene construction, use of a gene construct, paired two-component system, designed for use in a mammalian host, and process for transferring a cytotoxic drug to a site | |
DE69329735D1 (en) | PEPTIDE HYDROCARBON CONJUGATES WHICH T-CELL IMMUNITY | |
GR3035245T3 (en) | Protein targeting into hiv virions based on hiv-1 vpr fusion molecules | |
AU3677095A (en) | Radioactive phosphorous labeling of proteins for targeted radiotherapy | |
MY125980A (en) | Highly purified cytokine activating factor and methods of use | |
BR0016129A (en) | Nucleic acid molecule, recombinant vector, polypeptide, eukaryotic amino acid racemase, antibodies, host cell, methods to produce polypeptide, to detect a parasite and a eukaryotic protein, to screen active molecules, to detect and quantify the presence or absence of a sequence, to inhibit a eukaryotic protein, to produce a eukaryotic and d-aminoacid recombinant amino acid racemase and to prevent or inhibit infection, plasmid, immune complex, kit to detect a parasite, fragment of a polynucleotide, eukaryotic protein, processes to prepare a purified eukaryotic protein, to detect an infection and for infection and to screen a molecule, immunizing composition, vaccine composition, any molecular modification of the gene or a fragment of the gene, use of any molecular or biochemical modification of the enzymatic activity of the racemase, and , any molecule or composition to | |
BR9610050A (en) | Conjugate, combined two-component systems intended for use in a host, compounds or a pharmaceutically acceptable salt thereof, enzyme, polynucleotide and de02 nucleotide sequence, vector, host cell, enzyme and conjugate production processes and treatment of neoplastic cells in a host, pharmaceutical composition and plasmid | |
TR200101141T2 (en) | Pharmaceutical composition containing fragments of a DNA encoding antigenic protein with antitumor effect | |
AR011100A1 (en) | DNA OBTAINABLE FROM S. CLAVULIGERUS, VECTOR THAT INCLUDES SUCH DNA, HOSPITAL AGENCY, S. CLAVULIGERUS, PROCEDURE TO IMPROVE THE PRODUCTION OF 5R-CLAVAM IN A SUITABLE MICROORGANISM, A PRODUCTION MICROORGANISM AND PRODUCTION NULL OF 5S- | |
BR9709700A (en) | Viral vector cell pharmaceutical composition process of preparing in situ replicative circular DNA molecules using a viral vector process for the transfer of nucleic acids to a replicating circular DNA molecule | |
WO2022172083A3 (en) | Targeted nucleic acid therapy for hepatitis b | |
Okamoto et al. | In vitro expression of plasmid pUB110 DNA with Bacillus subtilis cell-free extracts | |
JO1766B1 (en) | New active compounds | |
BR9909480A (en) | Method for generating a cytotoxic t cell response from a specific hiv in a host |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB36 | Technical and formal requirements: requirement - article 36 of industrial property law | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: COM BASE NO ARTIGO 8O DA LPI DE 9279/96 COMBINADO COM O ARTIGO 13 DA LPI DE 9279/96, DECIDIMOS PELO INDEFERIMENTO DO PRESENTE PEDIDO. |
|
B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
B25D | Requested change of name of applicant approved |
Owner name: SYNGENTA LIMITED (GB) Free format text: ALTERADO DE: ZENECA LIMITED |
|
B25G | Requested change of headquarter approved |
Owner name: SYNGENTA LIMITED (GB) Free format text: ANOTADAS AS ALTERACOES DE SEDE, CONFORME SOLICITADO NA PETICAO NO 020070050229/RJ DE 19/04/2007. |
|
B25A | Requested transfer of rights approved |
Owner name: ASTRAZENECA UK LIMITED (GB) Free format text: TRANSFERIDO DE: SYNGENTA LIMITED |
|
B25A | Requested transfer of rights approved |
Owner name: LONDON BIOTECHNOLOGY LIMITED (GB) Free format text: TRANSFERIDO DE: ASTRAZENECA UK LIMITED |
|
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/10/2010, OBSERVADAS AS CONDICOES LEGAIS. |
|
B22O | Other matters related to patents and certificates of addition of invention: legal action concerning patent |
Free format text: INPI-52400.061577/2013 ORIGEM: JUIZO DA 013A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0132353-78.2013.4.02.5101 ACAO DE NULIDADE DAS PATENTES SUBMETIDAS AO MAILBOX (ART. 229, PARAGRAFO UNICO DA LPI); ALTERNATIVAMENTE, A DECRETACAO DA NULIDADE PARCIAL PARA CORRECAO DO PRAZO DE VIGENCIA; SUBSIDIARIAMENTE, CASO SE ENTENDA NAO SER O CASO DE NULIDADE, A CORRECAO DO ATO ADMINISTRATIVO PARA ADEQUACAO DA VIGENCIA DAS PATENTES. AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU: KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO, LONDON BIOTECHNOLOGY LIMITED, MERCK SHARP AND DOHME, N.V. ORGANON, NICOX S.A. |
|
B24C | Patent annual fee: request for for restoration |
Free format text: REFERENTE A 18A ANUIDADE. |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time | ||
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: MANUTENCAO DA EXTINCAO - ART. 78 INCISO IV DA LPI |
|
B15K | Others concerning applications: alteration of classification |
Ipc: B82Y 5/00 (2011.01), A61K 47/68 (2017.0 |
|
B19A | Notification of judicial decision: notification of judicial decision |
Free format text: INPI-52400.061577/2013-10 SECAO JUDICIARIA DO RIO DE JANEIRO 9A VARA FEDERAL DO RIO DE JANEIRO PROCESSO: NO0132353-78.2013.4.02.5101APELANTE: MERCK SHARP AND DOHME CORP E OUTROS APELADO: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL ? INPI DECISAO: A CONTROVERSIA SOBRE O PRAZO DE VIGENCIA DAS PATENTES MAILBOX FOI DEVIDAMENTE APRECIADA POR ESTE TRIBUNAL NO AMBITO DAS TURMAS ESPECIALIZADAS, ASSIM COMO TAMBEM NO DA SECAO, ALEM DO E. STJ, TENDO SIDO CONSOLIDADO O ENTENDIMENTO NO SENTIDO DE QUE O PARAGRAFO UNICO DO ARTIGO 40 DA LEI NO9.279/96 NAO SE APLICA AS PATENTES ?MAILBOX?, DIANTE DA LIMITACAO ESTABELECIDA PELO ARTIGO 229, PARAGRAFO UNICO, DA MESMA LEI DEVENDO SER APLICADO O PRAZO DE VIGE |